MX2016009491A - Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. - Google Patents

Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.

Info

Publication number
MX2016009491A
MX2016009491A MX2016009491A MX2016009491A MX2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A MX 2016009491 A MX2016009491 A MX 2016009491A
Authority
MX
Mexico
Prior art keywords
dpp4
antagonist
disorder
specific
biomarker
Prior art date
Application number
MX2016009491A
Other languages
English (en)
Inventor
Yao Yihong
Liang Meina
Streicher Katie
Ranade Koustubh
Vainshtein Inna
Piper Edward
May Richard
NORDENMARK Lars
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2016009491A publication Critical patent/MX2016009491A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis

Abstract

La presente invención se refiere al uso de DPP4 (por ejemplo, niveles de expresión de proteína o génicos) como biomarcador para enfermedades o trastornos mediados por IL-13, por ejemplo, asma, FPI, EPOC o dermatitis atópica. Los niveles del biomarcador DPP4 por encima o por debajo de un nivel umbral predeterminado de DPP4 pueden usarse, por ejemplo, (i) para determinar la elegibilidad de un paciente para un determinado tratamiento con un antagonista de IL-13, (ii) para determinar si un determinado tratamiento de una enfermedad o trastorno mediado por IL-13 con un antagonista de IL-13 debería comenzar, suspenderse o modificarse, (iii) para diagnosticar si una afección o trastorno mediado por IL-13 es tratable con un antagonista específico de IL-13, (iv) para pronosticar el resultado de tratar una enfermedad o trastorno mediado por IL-13 con un antagonista específico de IL-13, etc. La descripción proporciona además kits de ensayo para la detección de DPP4, así como para métodos diagnóstico implementados por ordenador.
MX2016009491A 2014-01-27 2015-01-26 Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico. MX2016009491A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931878P 2014-01-27 2014-01-27
US201461990932P 2014-05-09 2014-05-09
PCT/US2015/012885 WO2015112970A1 (en) 2014-01-27 2015-01-26 Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lung

Publications (1)

Publication Number Publication Date
MX2016009491A true MX2016009491A (es) 2017-01-13

Family

ID=53682019

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009491A MX2016009491A (es) 2014-01-27 2015-01-26 Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.

Country Status (12)

Country Link
US (1) US20160363591A1 (es)
EP (2) EP3099323A4 (es)
JP (1) JP2017509692A (es)
KR (1) KR20160113700A (es)
CN (1) CN105934254A (es)
AU (1) AU2015209124A1 (es)
BR (1) BR112016017192A2 (es)
CA (1) CA2937387A1 (es)
MX (1) MX2016009491A (es)
RU (1) RU2016134838A (es)
SG (1) SG11201606102UA (es)
WO (1) WO2015112970A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9862762B2 (en) * 2014-02-07 2018-01-09 Medimmune, Llc Monoclonal antibodies which bind human periostin
MX2017008748A (es) 2015-01-09 2017-11-17 Medimmune Llc Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana.
JP2018538249A (ja) * 2015-11-04 2018-12-27 アストラゼネカ アクチボラグ 好酸球性疾患における好酸球標的化治療薬に対する臨床応答の予測変数としてのジペプチジルペプチダーゼ−４およびペリオスチン
CN107474134B (zh) 2016-06-08 2021-07-27 苏州康乃德生物医药有限公司 用于结合白细胞介素4受体的抗体
UA124269C2 (uk) * 2016-09-23 2021-08-18 Дженентек, Інк. Застосування антагоністу il-13 для лікування атопічного дерматиту
US10386368B2 (en) 2017-02-24 2019-08-20 Trustees Of Boston University Isolation of human lung progenitors derived from pluripotent stem cells
CN109055522A (zh) * 2018-07-03 2018-12-21 吉林大学 C4orf38在制备用于检测或治疗神经性疼痛的产品中的应用
CN113155996A (zh) * 2021-03-23 2021-07-23 广州医科大学附属第一医院（广州呼吸中心） 15(s)-羟基二十碳四烯酸在评估变应原特异性免疫治疗效果中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
EP1631680A2 (en) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
AU2005214286A1 (en) * 2004-02-23 2005-09-01 Erasmus University Medical Center Rotterdam Classification, diagnosis and prognosis of acute myeloid leukemia by gene expression profiling
US20090155784A1 (en) * 2007-01-22 2009-06-18 Wyeth Assessment of asthma and allergen-dependent gene expression
US20120005206A1 (en) * 2007-02-09 2012-01-05 Konstantinos Anagnostakis Apparatus and method for analysis of data traffic
CN102099485A (zh) * 2007-10-23 2011-06-15 临床基因组学有限公司 诊断新生物的方法-ⅱ
SG2014014138A (en) 2008-03-31 2014-07-30 Genentech Inc Compositions and methods for treating and diagnosing asthma
US20100221752A2 (en) 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
JP2013544235A (ja) * 2010-10-15 2013-12-12 メドイミューン・リミテッド 肺機能を改善する治療法
NZ609493A (en) 2010-12-16 2015-11-27 Genentech Inc Diagnosis and treatments relating to th2 inhibition
EP2710370A4 (en) 2011-05-18 2015-01-07 Medimmune Llc METHODS OF DIAGNOSING AND TREATING PULMONARY DISEASES OR DISORDERS

Also Published As

Publication number Publication date
EP3099323A1 (en) 2016-12-07
US20160363591A1 (en) 2016-12-15
JP2017509692A (ja) 2017-04-06
EP3099323A4 (en) 2017-10-04
EP3685857A1 (en) 2020-07-29
SG11201606102UA (en) 2016-08-30
CA2937387A1 (en) 2015-07-30
RU2016134838A3 (es) 2018-09-27
RU2016134838A (ru) 2018-03-07
AU2015209124A1 (en) 2016-08-18
KR20160113700A (ko) 2016-09-30
WO2015112970A1 (en) 2015-07-30
BR112016017192A2 (pt) 2017-10-10
CN105934254A (zh) 2016-09-07

Similar Documents

Publication Publication Date Title
MX2016009491A (es) Dipeptidil peptidasa-4 (dpp4/cd26) como biomarcador periferico de activacion de interleucina 13 (il-13) en el pulmon asmatico.
WO2016077366A8 (en) Therapeutic and diagnostic methods for il-33-mediated disorders
WO2013008102A3 (en) Methods and compositions for evaluating and/or treating chronic immune diseases
MX371228B (es) Anticuerpos antiperiostina, kits, composiciones y su uso en la medición de periostina total.
MX2012001716A (es) Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
MX2016005159A (es) Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
NZ602618A (en) Aptamers to beta-ngf and their use in treating beta-ngf mediated diseases and disorders
MX2016002879A (es) Sistemas, dispositivos y metodos para la terapia anti-tl1a.
WO2015169966A3 (en) Methods for treating inflammatory bowel disease
NZ588853A (en) Compositions and methods for treating and diagnosing asthma
EP3683320A3 (en) Mirna fingerprint in the diagnosis of lung cancer
NZ584787A (en) Inhibition of angiogenesis with a Bv8 antagonist
MX2013000675A (es) Metodo para identificar a un paciente con incrementada probabilidad de responder a una terapia anticancer.
MX2018004170A (es) Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos.
MX2018007589A (es) Ccl20 como indicador de respuesta clinica a antagonistas de il23.
RU2017146409A (ru) Способы прогнозирования рака предстательной железы
MX2022014741A (es) Metodos para detectar bordetella.
WO2010118243A3 (en) Use of il-27 antagonists to treat lupus
IN2014DN08537A (es)
WO2017077391A3 (en) Dipeptidyl peptidase-4 and periostin as predictors of clinical response to eosinophil-targeted therapeutic agents in eosinophilic diseases
WO2011128820A3 (en) Methods for the analysis of breast cancer disorders
WO2013063062A3 (en) Il-19 as a biomarker of tslp treatment
EP2588630A4 (en) MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL AND DRUG INDEPENDENCE
WO2012061808A3 (en) Neuropsychiatric test reports
MX364003B (es) Tratamiento de resistencia a la insulina a traves de inhibidores del factor de transcripcion tsc22d4.